Last reviewed · How we verify
sunitinib malate dose escalation
At a glance
| Generic name | sunitinib malate dose escalation |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors (PHASE1)
- Losartan + Sunitinib in Treatment of Osteosarcoma (PHASE1)
- A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) (PHASE1)
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (PHASE3)
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (PHASE1)
- A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma (PHASE1)
- A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (PHASE1, PHASE2)
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sunitinib malate dose escalation CI brief — competitive landscape report
- sunitinib malate dose escalation updates RSS · CI watch RSS
- Pfizer portfolio CI